Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $178.71 Average Price Target from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has earned a consensus rating of “Moderate Buy” from the twenty-two analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $178.71.

A number of analysts have recently issued reports on SRPT shares. Guggenheim lifted their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Robert W. Baird lowered their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Raymond James reissued an “outperform” rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Finally, Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $152.00 to $167.00 in a report on Thursday, November 7th.

Sarepta Therapeutics Stock Down 0.9 %

Shares of NASDAQ SRPT opened at $114.45 on Friday. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high of $173.25. The firm has a market cap of $10.93 billion, a price-to-earnings ratio of 91.56 and a beta of 0.77. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock’s 50-day simple moving average is $122.81 and its 200-day simple moving average is $127.50.

Insider Transactions at Sarepta Therapeutics

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SRPT. Wellington Management Group LLP lifted its position in Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares during the period. Erste Asset Management GmbH acquired a new stake in Sarepta Therapeutics in the third quarter worth approximately $79,425,000. Janus Henderson Group PLC lifted its position in Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after purchasing an additional 543,143 shares during the period. Soros Fund Management LLC acquired a new stake in Sarepta Therapeutics in the third quarter worth approximately $25,800,000. Finally, Swedbank AB bought a new position in shares of Sarepta Therapeutics in the fourth quarter valued at $16,706,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.